Home » AGEB Journal » Issues » Volume 76" » Fasc.3 - Case series » Article details

The use of fecal calprotectin and lactoferrin in patients with IBD. Review

Journal Volume 76 - 2013
Issue Fasc.3 - Case series
Author(s) Elisabeth Stragier, Gert Van Assche
Full article
Full Article
VIEW FREE PDF
UZ Leuven, Leuven

Endoscopy has been the gold standard for diagnosing and fol- lowing patients with inflammatory bowel disease. However, ileoco- lonoscopy is still an expensive and invasive method. Secondly we do know that clinical scores for ulcerative colitis and Crohn's disease are subjective which creates several problems. And thirdly, when using the known serological markers such as C-reactive protein, white blood cell count en albumin, one should take into account that these markers are not perfect or superior to the current diag- nostic techniques given their low sensitivity and specificity. Fecal markers may prove to have a greater specificity. Calpro- tectin can differentiate between active and inactive inflammatory bowel disease and between inflammatory bowel disease and irrita- ble bowel syndrome. It correlates with the severity of symptoms and it may predict relapse especially in ulcerative colitis. Finally it can be used as a surrogate marker for the endoscopic response dur- ing treatment given a normal value of calprotectin is a reliable marker for mucosal healing. Lactoferrin also seems to be a sensi- tive and specific marker for the detection of chronic inflammation and for predicting relapse. The relationship with the endoscopic activity is significant and lactoferrin values are significantly higher in active endoscopic disease as compared to inactive disease. Finally, given the significant correlation with endoscopic activity, lactoferrin can function as an adequate marker for the monitoring of therapy. (Acta gastroenterol. belg., 2013, 76, 322-328).

© Acta Gastro-Enterologica Belgica.
PMID 24261027